Aura Biosciences, Inc.

NasdaqGM:AURA Stock Report

Market Cap: US$447.1m

Aura Biosciences Valuation

Is AURA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of AURA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AURA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AURA's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for AURA?

Key metric: As AURA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for AURA. This is calculated by dividing AURA's market cap by their current book value.
What is AURA's PB Ratio?
PB Ratio2.6x
BookUS$174.67m
Market CapUS$447.07m

Price to Book Ratio vs Peers

How does AURA's PB Ratio compare to its peers?

The above table shows the PB ratio for AURA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.8x
ARCT Arcturus Therapeutics Holdings
1.7x70.8%US$462.4m
TNGX Tango Therapeutics
1.8x-9.5%US$389.9m
SLRN Acelyrin
0.9x6.1%US$434.4m
KRRO Korro Bio
2.7x-15.1%US$490.1m
AURA Aura Biosciences
2.6x-8.9%US$447.1m

Price-To-Book vs Peers: AURA is expensive based on its Price-To-Book Ratio (2.6x) compared to the peer average (1.8x).


Price to Book Ratio vs Industry

How does AURA's PB Ratio compare vs other companies in the US Biotechs Industry?

60 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$550.38m
IMAB I-Mab
0.4x1.8%US$78.16m
ACET Adicet Bio
0.4x6.7%US$75.31m
MGX Metagenomi
0.3x-23.2%US$68.11m
AURA 2.6xIndustry Avg. 1.9xNo. of Companies82PB01.63.24.86.48+
60 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: AURA is expensive based on its Price-To-Book Ratio (2.6x) compared to the US Biotechs industry average (1.8x).


Price to Book Ratio vs Fair Ratio

What is AURA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AURA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AURA's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AURA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.95
US$22.43
+150.6%
5.3%US$24.00US$20.00n/a7
Nov ’25US$10.15
US$22.43
+121.0%
5.3%US$24.00US$20.00n/a7
Oct ’25US$8.58
US$21.00
+144.8%
6.7%US$23.00US$19.00n/a7
Sep ’25US$7.95
US$20.00
+151.6%
4.1%US$21.00US$19.00n/a6
Aug ’25US$9.86
US$20.00
+102.8%
4.1%US$21.00US$19.00n/a6
Jul ’25US$7.37
US$19.80
+168.7%
3.8%US$21.00US$19.00n/a5
Jun ’25US$7.35
US$19.80
+169.4%
3.8%US$21.00US$19.00n/a5
May ’25US$7.65
US$19.80
+158.8%
3.8%US$21.00US$19.00n/a5
Apr ’25US$7.76
US$19.80
+155.2%
3.8%US$21.00US$19.00n/a5
Mar ’25US$9.24
US$19.80
+114.3%
3.8%US$21.00US$19.00n/a5
Feb ’25US$7.77
US$19.80
+154.8%
3.8%US$21.00US$19.00n/a5
Jan ’25US$8.86
US$19.80
+123.5%
3.8%US$21.00US$19.00n/a5
Dec ’24US$8.18
US$25.00
+205.6%
30.0%US$38.00US$19.00n/a5
Nov ’24US$8.97
US$27.40
+205.5%
21.7%US$38.00US$21.00US$10.155
Oct ’24US$8.97
US$27.40
+205.5%
21.7%US$38.00US$21.00US$8.585
Sep ’24US$10.44
US$27.40
+162.5%
21.7%US$38.00US$21.00US$7.955
Aug ’24US$11.87
US$28.80
+142.6%
18.6%US$38.00US$23.00US$9.865
Jul ’24US$12.35
US$30.25
+144.9%
16.6%US$38.00US$24.00US$7.374
Jun ’24US$12.08
US$30.25
+150.4%
16.6%US$38.00US$24.00US$7.354
May ’24US$9.06
US$30.50
+236.6%
15.5%US$38.00US$25.00US$7.654
Apr ’24US$9.28
US$30.50
+228.7%
15.5%US$38.00US$25.00US$7.764
Mar ’24US$10.10
US$31.75
+214.4%
11.4%US$38.00US$29.00US$9.244
Feb ’24US$10.30
US$31.75
+208.3%
11.4%US$38.00US$29.00US$7.774
Jan ’24US$10.50
US$31.75
+202.4%
11.4%US$38.00US$29.00US$8.864
Dec ’23US$13.42
US$31.75
+136.6%
11.4%US$38.00US$29.00US$8.184
Nov ’23US$12.51
US$30.75
+145.8%
14.4%US$38.00US$26.00US$8.974

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies